

# Imunoterapie myelomu: Od IMiDů k cílené terapii

Jakub Radocha

IV. interní hematologická klinika LF UK a FNHK




**IV. INTERNÍ HEMATOLOGICKÁ KLINIKA  
FAKULTNÍ NEMOCNICE HRADEC KRÁLOVÉ**




Regionální hematologický seminář východočeského a libereckého regionu 12.11.2021

# Imunoterapie = snaha stimulovat imunitní systém, aby rozpoznal a ničil nádorové buňky






# 22 let léčby myelomu IMiD

Thalid




omid






Thalidomide  
Lenalidomide  
Pomalidomide




# První linie – TE pacient




## Udržovací léčba lenalidomidem:

- Standard léčby pacientů po ASCT
- V ČR hrazena od 1.6. 2020




# První linie – T1 pacient




## VRd:


- V současnosti hrazená léčba první volby
- V ČR hrazena od 1. 4. 2021 (VILP)



# Relaps / refrakterní MM




# Povrchové znaky = cíle imunoterapie






Povrchové znaky = cíle imunoterapie




**CDC**

komplementem zprostředkovaná cytotoxicita




**ADCC**


na protlátkách závislá cytotoxicita



**ADCC**

na protlátkách závislá fagocytóza






No. at risk

Rd	283	249	206	181	160	144	1
D-Rd	286	266	249	238	229	215	2


A.



No. at risk


Vd	247	182	129	74	39
D-Vd	251	215	198	161	136

ITT population




	No. of Patients	Median Progression-free Survival (mo)
Daratumumab	350	NE

Per




No. at risk

Rd	369	332	307	281
DRd	368	347	335	312



No. at Risk

	0	3	6	9
Daratumumab	350	322	312	298
Control	356	303	278	261



Number at risk

	0	3	6	9	12	15	18	21	24	27	30	33
D-VTd	543	520	501	492	442	346	261	185	122	61	14	0
VTd	542	519	497	475	413	319	233	163	104	50	14	0

Taurus Mars

Cepheus



Cygnus



## Výsledky léčby MoAB




Study	Regimen	Population	Phase	>VGPR	>CR	MRD-	PFS
Pollux	Dara-RD vs RD	RRMM	3	75.8% vs 44.2%	43.1% vs 19.2%	22.4% vs 4.9%	44.5 vs 17.5 m
Castor	Dara-VD vs VD	RRMM	3	59.2% vs 29.1%	19.2% vs 9%	NA	16.7 vs 7.1 m
Apollo	Dara-PD vs PD	RRMM	3	51.0% vs 19.6%	24.5% vs 3.9%	9% vs 2%	12.4 vs 6.9 m
Alcyone	Dara-VMP vs VMP	TI NDMM	3	71.1% vs 49.7%	42.6% vs 24.4%	22.3% vs 6.2%	36.4 vs 19.3 m
Maia	Dara-RD vs RD	TI NDMM	3	79.3% vs 53.1%	47.6% vs 24.9%	24.2% vs 7.30	NR vs. 34 m
Cassiopeia	Dara-VTD vs VTD	TE NDMM	3	83% vs 78%	39% vs 26%	64% vs 44%	NR vs NR
Griffin	Dara-VRD vs VRD	TE NDMM	3	90.9% vs 73.2%	51.5% vs 42.3%	51% vs 20.4%	NR vs NR
Ikema	Isa-KD, KD	RRMM	3	69.2% vs 48.7 %	28.5% vs 10.4 %	13.8% vs 3.2 %	NR and 19.5 m
Icaria	Isa-PD vs PD	RRMM	3	32.0% vs 9.0%	5% vs 1%	5% vs 0%	11.5 vs 6.5 m




b

# Monoklonální protilátky – konjugáty







# Výsledky léčby ADC




Study	Phase	NCT number	Target	Payload	Mechanism of action	No. of patients	Prior lines	ORR
Belantamab mafodotin (DREAMM-1)	1	NCT02064387	BCMA	MMAF	Tubulin inhibitor	35	5	<b>60%</b>
Belantamab mafodotin (DREAMM-2)	2	NCT03525678	BCMA	MMAF	Tubulin inhibitor	97/99	6/7	<b>31% / 35%</b>
AMG224	1	NCT02561962	BCMA	Mertansine (DM1)	Tubulin inhibitor	29/11	7	<b>21% / 27%</b>
MEDI2228	1	NCT03489525	BCMA	Pyrrrolobenzodiazepine dimer	DNA damage	82	2-11 lines	<b>61.0%</b>
Indatuximab-ravtansine	1	NCT01001442	CD138	DM4	Tubulin inhibitor	35	7	<b>6%</b>
Lorvotuzumab-mertansine	1	NCT00991562	CD56	DM1	Tubulin inhibitor	37	1-6 lines	<b>6%</b>










# Bispecifické protilátky – recentní data









# CAR-T ide-cel





# CAR-T ide-cel





# CAR-T cilta-cel

